Global Primary Biliary Cholangitis Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030
1 Market Overview
- 1.1 Product Overview and Scope of Primary Biliary Cholangitis Therapeutics
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Primary Biliary Cholangitis Therapeutics by Type
- 1.3.1 Overview: Global Primary Biliary Cholangitis Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
- 1.3.2 Global Primary Biliary Cholangitis Therapeutics Consumption Value Market Share by Type in 2023
- 1.3.3 OCALIVA
- 1.3.4 Ursodiol
- 1.3.5 Others
- 1.4 Global Primary Biliary Cholangitis Therapeutics Market by Application
- 1.4.1 Overview: Global Primary Biliary Cholangitis Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
- 1.4.2 Hospital
- 1.4.3 Private Clinic
- 1.4.4 Other
- 1.5 Global Primary Biliary Cholangitis Therapeutics Market Size & Forecast
- 1.6 Global Primary Biliary Cholangitis Therapeutics Market Size and Forecast by Region
- 1.6.1 Global Primary Biliary Cholangitis Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
- 1.6.2 Global Primary Biliary Cholangitis Therapeutics Market Size by Region, (2019-2030)
- 1.6.3 North America Primary Biliary Cholangitis Therapeutics Market Size and Prospect (2019-2030)
- 1.6.4 Europe Primary Biliary Cholangitis Therapeutics Market Size and Prospect (2019-2030)
- 1.6.5 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size and Prospect (2019-2030)
- 1.6.6 South America Primary Biliary Cholangitis Therapeutics Market Size and Prospect (2019-2030)
- 1.6.7 Middle East and Africa Primary Biliary Cholangitis Therapeutics Market Size and Prospect (2019-2030)
2 Company Profiles
- 2.1 Abbott Laboratories
- 2.1.1 Abbott Laboratories Details
- 2.1.2 Abbott Laboratories Major Business
- 2.1.3 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Product and Solutions
- 2.1.4 Abbott Laboratories Primary Biliary Cholangitis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.1.5 Abbott Laboratories Recent Developments and Future Plans
- 2.2 Allergan Plc
- 2.2.1 Allergan Plc Details
- 2.2.2 Allergan Plc Major Business
- 2.2.3 Allergan Plc Primary Biliary Cholangitis Therapeutics Product and Solutions
- 2.2.4 Allergan Plc Primary Biliary Cholangitis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.2.5 Allergan Plc Recent Developments and Future Plans
- 2.3 Eli Lilly and Co.
- 2.3.1 Eli Lilly and Co. Details
- 2.3.2 Eli Lilly and Co. Major Business
- 2.3.3 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Product and Solutions
- 2.3.4 Eli Lilly and Co. Primary Biliary Cholangitis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.3.5 Eli Lilly and Co. Recent Developments and Future Plans
- 2.4 Intercept Pharmaceuticals Inc.
- 2.4.1 Intercept Pharmaceuticals Inc. Details
- 2.4.2 Intercept Pharmaceuticals Inc. Major Business
- 2.4.3 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Product and Solutions
- 2.4.4 Intercept Pharmaceuticals Inc. Primary Biliary Cholangitis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.4.5 Intercept Pharmaceuticals Inc. Recent Developments and Future Plans
- 2.5 Takeda Pharmaceutical Co. Ltd.
- 2.5.1 Takeda Pharmaceutical Co. Ltd. Details
- 2.5.2 Takeda Pharmaceutical Co. Ltd. Major Business
- 2.5.3 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Product and Solutions
- 2.5.4 Takeda Pharmaceutical Co. Ltd. Primary Biliary Cholangitis Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
- 2.5.5 Takeda Pharmaceutical Co. Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Primary Biliary Cholangitis Therapeutics Revenue and Share by Players (2019-2024)
- 3.2 Market Share Analysis (2023)
- 3.2.1 Market Share of Primary Biliary Cholangitis Therapeutics by Company Revenue
- 3.2.2 Top 3 Primary Biliary Cholangitis Therapeutics Players Market Share in 2023
- 3.2.3 Top 6 Primary Biliary Cholangitis Therapeutics Players Market Share in 2023
- 3.3 Primary Biliary Cholangitis Therapeutics Market: Overall Company Footprint Analysis
- 3.3.1 Primary Biliary Cholangitis Therapeutics Market: Region Footprint
- 3.3.2 Primary Biliary Cholangitis Therapeutics Market: Company Product Type Footprint
- 3.3.3 Primary Biliary Cholangitis Therapeutics Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Primary Biliary Cholangitis Therapeutics Consumption Value and Market Share by Type (2019-2024)
- 4.2 Global Primary Biliary Cholangitis Therapeutics Market Forecast by Type (2025-2030)
5 Market Size Segment by Application
- 5.1 Global Primary Biliary Cholangitis Therapeutics Consumption Value Market Share by Application (2019-2024)
- 5.2 Global Primary Biliary Cholangitis Therapeutics Market Forecast by Application (2025-2030)
6 North America
- 6.1 North America Primary Biliary Cholangitis Therapeutics Consumption Value by Type (2019-2030)
- 6.2 North America Primary Biliary Cholangitis Therapeutics Consumption Value by Application (2019-2030)
- 6.3 North America Primary Biliary Cholangitis Therapeutics Market Size by Country
- 6.3.1 North America Primary Biliary Cholangitis Therapeutics Consumption Value by Country (2019-2030)
- 6.3.2 United States Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 6.3.3 Canada Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 6.3.4 Mexico Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
7 Europe
- 7.1 Europe Primary Biliary Cholangitis Therapeutics Consumption Value by Type (2019-2030)
- 7.2 Europe Primary Biliary Cholangitis Therapeutics Consumption Value by Application (2019-2030)
- 7.3 Europe Primary Biliary Cholangitis Therapeutics Market Size by Country
- 7.3.1 Europe Primary Biliary Cholangitis Therapeutics Consumption Value by Country (2019-2030)
- 7.3.2 Germany Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 7.3.3 France Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 7.3.4 United Kingdom Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 7.3.5 Russia Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 7.3.6 Italy Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
8 Asia-Pacific
- 8.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Consumption Value by Type (2019-2030)
- 8.2 Asia-Pacific Primary Biliary Cholangitis Therapeutics Consumption Value by Application (2019-2030)
- 8.3 Asia-Pacific Primary Biliary Cholangitis Therapeutics Market Size by Region
- 8.3.1 Asia-Pacific Primary Biliary Cholangitis Therapeutics Consumption Value by Region (2019-2030)
- 8.3.2 China Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 8.3.3 Japan Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 8.3.4 South Korea Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 8.3.5 India Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 8.3.6 Southeast Asia Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 8.3.7 Australia Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
9 South America
- 9.1 South America Primary Biliary Cholangitis Therapeutics Consumption Value by Type (2019-2030)
- 9.2 South America Primary Biliary Cholangitis Therapeutics Consumption Value by Application (2019-2030)
- 9.3 South America Primary Biliary Cholangitis Therapeutics Market Size by Country
- 9.3.1 South America Primary Biliary Cholangitis Therapeutics Consumption Value by Country (2019-2030)
- 9.3.2 Brazil Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 9.3.3 Argentina Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
10 Middle East & Africa
- 10.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Consumption Value by Type (2019-2030)
- 10.2 Middle East & Africa Primary Biliary Cholangitis Therapeutics Consumption Value by Application (2019-2030)
- 10.3 Middle East & Africa Primary Biliary Cholangitis Therapeutics Market Size by Country
- 10.3.1 Middle East & Africa Primary Biliary Cholangitis Therapeutics Consumption Value by Country (2019-2030)
- 10.3.2 Turkey Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 10.3.3 Saudi Arabia Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
- 10.3.4 UAE Primary Biliary Cholangitis Therapeutics Market Size and Forecast (2019-2030)
11 Market Dynamics
- 11.1 Primary Biliary Cholangitis Therapeutics Market Drivers
- 11.2 Primary Biliary Cholangitis Therapeutics Market Restraints
- 11.3 Primary Biliary Cholangitis Therapeutics Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Primary Biliary Cholangitis Therapeutics Industry Chain
- 12.2 Primary Biliary Cholangitis Therapeutics Upstream Analysis
- 12.3 Primary Biliary Cholangitis Therapeutics Midstream Analysis
- 12.4 Primary Biliary Cholangitis Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Primary Biliary Cholangitis Therapeutics market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Primary Biliary Cholangitis Therapeutics industry chain, the market status of Hospital (OCALIVA, Ursodiol), Private Clinic (OCALIVA, Ursodiol), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Primary Biliary Cholangitis Therapeutics.
Regionally, the report analyzes the Primary Biliary Cholangitis Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Primary Biliary Cholangitis Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Primary Biliary Cholangitis Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Primary Biliary Cholangitis Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., OCALIVA, Ursodiol).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Primary Biliary Cholangitis Therapeutics market.
Regional Analysis: The report involves examining the Primary Biliary Cholangitis Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Primary Biliary Cholangitis Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Primary Biliary Cholangitis Therapeutics:
Company Analysis: Report covers individual Primary Biliary Cholangitis Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Primary Biliary Cholangitis Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Private Clinic).
Technology Analysis: Report covers specific technologies relevant to Primary Biliary Cholangitis Therapeutics. It assesses the current state, advancements, and potential future developments in Primary Biliary Cholangitis Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Primary Biliary Cholangitis Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Primary Biliary Cholangitis Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
OCALIVA
Ursodiol
Others
Market segment by Application
Hospital
Private Clinic
Other
Market segment by players, this report covers
Abbott Laboratories
Allergan Plc
Eli Lilly and Co.
Intercept Pharmaceuticals Inc.
Takeda Pharmaceutical Co. Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Primary Biliary Cholangitis Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Primary Biliary Cholangitis Therapeutics, with revenue, gross margin and global market share of Primary Biliary Cholangitis Therapeutics from 2019 to 2024.
Chapter 3, the Primary Biliary Cholangitis Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Primary Biliary Cholangitis Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Primary Biliary Cholangitis Therapeutics.
Chapter 13, to describe Primary Biliary Cholangitis Therapeutics research findings and conclusion.